Food and Drug Administration Requires Strong Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risks and Death From Combined Use

首页> 外文期刊>Journal of pain & palliative care pharmacotherapy >Food and Drug Administration Requires Strong Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risks and Death From Combined Use

【24h】

Food and Drug Administration Requires Strong Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risks and Death From Combined Use

机译：食品和药物管理局需要强烈的阿片类镇痛药，处方阿片类药物咳嗽产品和苯二氮卓标签，与综合使用的严重风险和死亡有关

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced on August 31, 2016, that it is requiring class-wide changes to drug labeling, including patient information, to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system (CNS) depressant drugs called benzodiazepines.

机译：经过广泛审查最新的科学证据，美国食品和药物管理局于2016年8月31日宣布，这需要对药物标签的全类变化，包括患者信息，帮助通知医疗保健提供者和严重的患者与某些阿片类药物和一类中枢神经系统（CNS）抑制药物相关的风险相关的风险，称为苯并二氮杂卓。

著录项

来源
《Journal of pain & palliative care pharmacotherapy》 |2016年第4期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Food and Drug Administration Requires Strong Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risks and Death From Combined Use [J] . Journal of pain & palliative care pharmacotherapy . 2016,第4期

机译：食品和药物管理局需要强烈的阿片类镇痛药，处方阿片类药物咳嗽产品和苯二氮卓标签，与综合使用的严重风险和死亡有关
2. Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids [J] . Liang Di, Shi Yuyan Drug and alcohol review . 2019,第5期

机译：处方药监测程序和药物过量死亡涉及苯并二氮卓和处方阿片类药物
3. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records [J] . John Macleod, Colin Steer, Kate Tilling, PLoS Medicine . 2019,第11期

机译：苯二氮卓，Z-药物和朱蓬萘肽的处方和人们接受阿片激动剂治疗的死亡风险：基于英国临床实践研究Datalink和国家统计死亡记录办公室的观察研究
4. Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving US Food and Drug Administration Premarket Approval in 2010 and 2011. [D] . Rathi, Vinay Kumar. 2016

机译：在2010年和2011年获得美国食品药品监督管理局上市前批准的高风险治疗性医疗器械整个产品生命周期中进行的临床研究。
5. Prescription of benzodiazepines z-drugs and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records [O] . John Macleod, Colin Steer, Kate Tilling, 2019

机译：接受阿片类激动剂治疗的人的苯二氮卓类药物z药物和加巴喷丁胺的处方及死亡风险：基于英国临床实践研究数据链和国家统计局死亡记录的观察性研究
6. Food and Drug Administration Requires Strong Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risks and Death From Combined Use [O] . 2016

机译：食品和药物管理局需要对阿片类镇痛药，处方阿片类药物咳嗽产品和苯二氮卓标记相关的强烈警告与综合使用中严重的风险和死亡相关
7. PDUFA Financial Report (FY 2004) Required by the Prescription Drug User Fee Act of 1992 as Amended by the Food and Drug Administration Modernization Act of 1997 and by the Prescription Drug User Fee Amendments of 2002 [R] . 2005

机译：pDUFa财务报告（2004财年）根据1997年食品药品管理局现代化法案和2002年处方药用户费修正案修订的1992年处方药用户费法案要求

Food and Drug Administration Requires Strong Warnings for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepine Labeling Related to Serious Risks and Death From Combined Use

摘要

著录项

相似文献

相关主题

期刊订阅